Steakholder Foods Ltd. (STKH)

Intra-Cellular Therapies Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	0.01	-	-	-	-
Cost of Revenue	0.02	-	-	-	-
Gross Profit	-0.01	-	-	-	-
Selling, General & Admin	4.95	7.08	10.57	8.65	5.89
Research & Development	3.52	7.1	6.53	4.78	2.49
Operating Expenses	8.46	14.18	17.1	13.43	8.38
Operating Income	-8.48	-14.18	-17.1	-13.43	-8.38
Interest Expense	-0.05	-1.37	-	-	-0.01
Interest & Investment Income	-	-	2.57	9.57	-
Currency Exchange Gain (Loss)	-	-	-	-	-0.09
Other Non Operating Income (Expenses)	-	-	-	-	0.11
EBT Excluding Unusual Items	-8.52	-15.55	-14.53	-3.86	-8.36
Other Unusual Items	-	-	-	-	-10.16
Pretax Income	-8.52	-15.55	-14.53	-3.86	-18.52
Earnings From Continuing Operations	-8.52	-15.55	-14.53	-3.86	-18.52
Earnings From Discontinued Operations	-	-1.32	-7.33	-18.06	-
Net Income	-8.52	-16.86	-21.86	-21.92	-18.52
Net Income to Common	-8.52	-16.86	-21.86	-21.92	-18.52
Shares Outstanding (Basic)	418	237	136	116	60
Shares Outstanding (Diluted)	418	237	136	116	60
Shares Change (YoY)	76.48%	74.13%	17.20%	92.90%	208.51%
EPS (Basic)	-0.02	-0.07	-0.16	-0.19	-0.31
EPS (Diluted)	-0.02	-0.07	-0.16	-0.19	-0.31
Free Cash Flow	-9.44	-13	-17.72	-16.21	-4.51
Free Cash Flow Per Share	-0.02	-0.06	-0.13	-0.14	-0.07
Gross Margin	-120.00%	-	-	-	-
Operating Margin	-84760.00%	-	-	-	-
Profit Margin	-85210.00%	-	-	-	-
Free Cash Flow Margin	-94430.00%	-	-	-	-
EBITDA	-8.01	-13.68	-16.26	-13.05	-8.31
D&A For EBITDA	0.47	0.5	0.84	0.38	0.07
EBIT	-8.48	-14.18	-17.1	-13.43	-8.38
Advertising Expenses	-	-	-	-	0.09

Updated Aug 30, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q